← Back
Astrazeneca
AZN · listed on the New York Stock Exchange · worth $289.48 billion
$186.65
+7.02% on Oct 30
No insider bought Astrazeneca stock in the last year. They sold it 1 time, $2.21 million in all. Four members of Congress reported trading Astrazeneca in the last year.
Red dot = an insider soldA number = that many on nearby days · click a mark to see who, or read the filing
Reverse split 1-for-2 in Feb 2026. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what AZN ever actually traded at. The drop is real, but those huge old numbers aren't.
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
1.5B shares
100% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, one insider sold Astrazeneca stock and none bought. None of the 1 sale is marked on its filing as planned in advance; all by company executives.
US Congress
Members of Congress who reported trading Astrazeneca in the last year. They have up to 45 days to report, so the newest trades show up late.
MemberTradeAmountWhose accountTradedReported
All reports
Every insider trade and SEC report we hold for Astrazeneca.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Analysts, earnings and news
Analysts' price target
$224.49 average
10 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
1 of 1 quarters above
Q1 '26$1.29 a share+$0.02